Live attenuated vaccines for pneumoviruses and related methods and materials

Patent metadata

Field	Value
Publication number	US-10465170-B2
Application number	US-201615552212-A
Country	US
Kind code	B2
Filing date	Feb 22, 2016
Priority date	Feb 20, 2015
Publication date	Nov 5, 2019
Grant date	Nov 5, 2019

Abstract

Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed. The vaccine compositions and methods described herein can be used to prevent metapneumovirus and respiratory syncytial virus infection in humans, respiratory syncytial virus infection in cattle, avian metapneumovirus infection in various avian species, and pneumonia virus of mice in rodents.

First claim

What is claimed is:

1. An attenuated recombinant pneumovirus comprising a mutated zinc binding domain in an M2-1 protein of the pneumovirus , wherein at least one amino acid of the zinc binding domain is mutated relative to wildtype pneumovirus , and wherein the at least one amino acid mutation comprises at least one of C21S and H25L.

2. The attenuated recombinant pneumovirus of claim 1 , wherein the at least one amino acid mutation in the zinc binding domain is non-lethal and abolishes zinc binding activity of the M2-1 protein.

3. The attenuated recombinant pneumovirus of claim 1 , wherein the at least one amino acid mutation further comprises at least one of C7S and C15S.

4. The attenuated recombinant pneumovirus of claim 1 , wherein the mutated zinc binding domain comprises at least one amino acid mutation at an amino acid selected from the group consisting of: C21; and H25, and at least one amino acid mutation at an amino acid selected from the group consisting of: C7 and C15.

5. The attenuated recombinant pneumovirus of claim 1 , wherein the pneumovirus is selected from the group consisting of: human metapneumovirus ; avian metapneumovirus ; human respiratory syncytial virus; bovine respiratory syncytial virus; and pneumonia virus of mice.

6. The attenuated recombinant pneumovirus of claim 1 , wherein the pneumovirus is a metapneumovirus or a respiratory syncytial virus.

7. A vaccine composition comprising the attenuated recombinant pneumovirus of claim 1 .

8. The vaccine composition of claim 7 , further comprising at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable vehicle, a pharmaceutically acceptable excipient, and a pharmaceutically acceptable adjuvant.

9. A method for inducing a protective immune response in a subject, comprising administering to the subject an immunologically effective dose of the vaccine composition of claim 7 .

10. The method of claim 9 , wherein the vaccine composition is administered via an administration route selected from the group consisting of: intranasal administration; subcutaneous administration; intramuscular administration; intradermal administration; and oral administration.

11. The method of claim 9 , further comprising administering at least one subsequent immunologically effective dose of the vaccine composition.

12. The method of claim 11 , wherein the at least one subsequent dose is administered at an interval selected from the group consisting of: approximately one week after the first dose; approximately two weeks after the first dose; approximately three weeks after the first dose; approximately four weeks after the first dose; approximately five weeks after the first dose; approximately six weeks after the first dose; approximately seven weeks after the first dose; and approximately eight weeks after the first dose.

13. The method of claim 9 , wherein the subject is an individual selected from the group consisting of: humans; fowl; cattle; and rodents.

14. The method of claim 9 , wherein the protective immune response protects the subject from viral challenge by a virus selected from the group consisting of: human metapneumovirus subtype A; human metapneumovirus subtype B; avian metapneumovirus subtype A; avian metapneumovirus subtype B; avian metapneumovirus subtype C; avian metapneumovirus subtype D; human respiratory syncytial virus type A; human respiratory syncytial virus type B; bovine respiratory syncytial virus; and pneumonia virus of mice.

15. A method for preparing the vaccine composition of claim 7 , comprising mixing the attenuated recombinant pneumovirus of claim 1 with at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable vehicle, a pharmaceutically acceptable excipient, and a pharmaceutically acceptable adjuvant.

16. The method of claim 15 , wherein the vaccine composition is formulated for administration via an administration route selected from the group consisting of: intranasal administration; subcutaneous administration; intramuscular administration; intradermal administration; and oral administration.

17. A kit comprising the vaccine composition of claim 7 , and at least one container.

Assignees

• Res Inst Nationwide Childrens Hospital
• Ohio State Innovation Foundation

Inventors

• Peeples Mark E
• Li Jianrong
• Cai Hui
• Wang Rongzhang

Classifications

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K2319/23

  containing a GST-tag · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• C12N2760/18562

  by genetic engineering · CPC title